Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for alopecia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alopecia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on alopecia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
primary efficacy end points were successful hair preservation assessed using the Common Terminology Criteria for Adverse Events version 4.0 scale (grade 0 [no hairloss] or grade 1 [<50% hairloss not requiring a wig] were considered to have hair preservation) at the end of 4 cycles of chemotherapy by a clinician unaware of treatment assignment, and device safety. Secondary end points included wig use and scores on the European Organisation for Research and Treatment of Cancer Quality of Life (...) ; 54 adverse events were reported in the cooling group, all grades 1 and 2. There were no serious adverse device events.Among women with stage I to II breast cancer receiving chemotherapy with a taxane, anthracycline, or both, those who underwent scalp cooling were significantly more likely to have less than 50% hairloss after the fourth chemotherapy cycle compared with those who received no scalp cooling. Further research is needed to assess longer-term efficacy and adverse
, producing circular areas of loss. Total loss of scalp hair ( alopecia totalis) or scalp (...) and body hair ( alopecia universalis) occurs less commonly. The exact cause of alopecia areata is unknown. Alopecia areata is a relatively common condition. It has been estimated that it affects 15 people in 10,000 of the UK population. It can present at any age but 60% of people develop their first bald patch before 20 years of age. The progress of alopecia areata is unpredictable. Patchy alopecia areata (...) involving less than 40% of the scalp is usually self-limiting and regrowth can be expected within 2014 2. Interventions for alopecia areata. BACKGROUND: Alopecia areata is a disorder in which there is loss of hair causing patches of baldness but with no scarring of the affected area. It can affect the entire scalp ( alopecia totalis) or cause loss of all body hair ( alopecia universalis). It is a relatively common condition affecting 0.15% of the population. Although in many cases it can be a self
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. Chemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited.To evaluate whether use of a scalp cooling system is associated with a lower amount of hairloss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes (...) months). No participants in the scalp cooling group received anthracyclines. Hairloss of 50% or less (Dean score of 0-2) was seen in 67 of 101 patients (66.3%; 95% CI, 56.2%-75.4%) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients (0%) in the control group (P < .001). Three of 5 quality-of-life measures were significantly better 1 month after the end of chemotherapy in the scalp cooling group. Of patients who underwent scalp cooling, 27.3% (95% CI, 18.0%-36.6%) reported feeling
Androgenic alopecia Androgenic alopecia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Androgenic alopecia Last reviewed: February 2019 Last updated: March 2018 Summary Also known as pattern baldness, androgenic alopecia is a genetically determined, patterned, progressive loss of hair from the scalp and occurs in both men and women. Both androgens and genetics play a role in its pathogenesis. The term androgenic (...) alopecia is best used only when referring to male-pattern hairloss, as most females likely do not share the androgenic pathway. A more appropriate term for women is female-pattern hairloss. The term pattern hairloss will be used when referring to hairloss affecting both sexes. Men present with hair thinning in the temporal areas that advances to the crown (vertex) area as the alopecia progresses. Women usually have more diffuse thinning on the crown area, and less commonly present with a male-type
and there is no known race or sex preponderance. Alopecia areata usually presents as patches of hairloss on the scalp but any hair-bearing skin can be involved. The affected skin may be slightly reddened but otherwise appears normal. Short broken hairs (exclamation mark hairs) are frequently seen around the margins of expanding patches of alopecia areata. The nails are involved in about 10% of patients referred for specialist advice. 6.1 Prognosis Hair follicles are preserved in alopecia areata and the po- tential (...) for recovery of hair growth is maintained, even in longstanding disease. One study from Japan reported that spontaneous remission within 1 year occurred in 80% of patients with a small number of circumscribed patches of hairloss. 3 Data from secondary and tertiary referral centres are less favourable indicating that 34–50% of patients will recover within 1 year. Almost all will experience more than one episode of the disease, and 14–25% progress to total loss of scalp hair (alopecia totalis, AT) or loss
Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens. Hairloss as a result of chemotherapy for early breast cancer (EBC) is a frequent and distressing side effect. Minimising hairloss may improve mood and body image. Our aim was to determine scalp cooling (SC) efficacy in EBC patients receiving contemporary chemotherapy regimen, to inform future patients choice to use SC or not.Prospective cohort study of 60 stage 1-3 EBC (...) patients recommended to receive taxane or anthracycline-taxane chemotherapy regimens. The primary outcome was incidence of minimal hair-loss (MHL - defined as 60% Dean grade 1 or 2). Patients were categorised by chemotherapy (3 groups) and randomised 1:1 within each group to two scalp cooling temperature settings using the Dignitana Dignicap machine (secondary endpoint). Patients reported degree of hairloss using the Dean score on day 1 of each cycle and following the last chemotherapy.On an intention
in the prevention of docetaxel-induced alopecia. Eur J Cancer 1997;33(2):297-300. Edelstyn GA, MacDonald M, MacRae KD. Doxorubicin-induced hairloss and possible modification by scalp cooling. Lancet 1977;2(8031):253-4. Satterwhite B, Zimm S. The use of scalp hypothermia in the prevention of doxorubicin-induced hairloss. Cancer 1984;54(1):34-7. Kennedy M, Packard R, Grant M, Padilla G, Presant C, Chillar R. The effects of using Chemocap on occurrence of chemotherapy-induced alopecia. Oncol Nurs Forum 1983;10(1 (...) ):19-24. Parker R. The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia. Oncol Nurs Forum 1987;14(6):49-53. Giaccone G, Di Giulio F, Morandini MP, Calciati A. Scalp hypothermia in the prevention of doxorubicin-induced hairloss. Cancer Nurs 1988;11(3):170-3. Macduff C, Mackenzie T, Hutcheon A, Melville L, Archibald H. The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel. Eur J Cancer Care (Engl) 2003;12(2):154-61
Clinical and Histopathological Findings of Frontal Fibrosing Alopecia-Associated Lichen Planus Pigmentosus Frontal fibrosing alopecia (FFA) is a primary lymphocytic scarring alopecia occurring mainly in postmenopausal women. A range of facial lesions have been described in FFA, such as lichen planus (LP) pigmentosus, red dots, facial papules, and perifollicular and diffuse erythema. These lesions can be the first sign of FFA. LP pigmentosus is a rare variant of LP. The first description of LP
care research. www.acfp.ca October 11, 2016 Drugs for male- and female-pattern baldness: Just a hair bit more effective than doing nothing? Clinical Question: What is the effect of approved medications for androgenic alopecia in men and women? Bottom-line: For men using finasteride or minoxidil, one in 4-8 more than placebo will notice at least slight improvement in hair count over 6-12 months, with no clear evidence one is better. For every 84 men taking finasteride for hairloss, one extra (...) outcome. o Minoxidil 1-5% versus placebo: ? Patient-rated moderate improvement or better (26% versus 14%, NNT=8) ? Increase in hair count, +13 hairs/cm 2 , at 6-12 months. Context: • Prevalence of androgenic alopecia increases with age, with approximately ½ of men and ? of women balding after age 70. 10 • Numerous other interventions (like nutritional supplements or Handi-Dome Comb) have low quality evidence with inconsistent results. 9,11 • Only minoxidil for women or men, and finasteride for men
Alopecia areata Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4
Alopecia Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4
indicates they can influence the ultimate natural course of alopecia areata. Treatment modalities usually are considered first according to the extent of hairloss and the patient's age. Assessment of the efficacy of a treatment must be considered with care because the condition is highly unpredictable in presentation, evolution, and response to treatment. Little data exist regarding the natural evolution of the condition. For example, in patients with less than 40% scalp involvement, a study showed (...) no benefit with treatment (minoxidil 1% and topical immunotherapy) over placebo. [ ] The high spontaneous remission rate makes clearly assessing the true efficacy of a therapy difficult unless appropriate controls with placebo treatment are studied. For patients with extensive alopecia areata (>40% hairloss), little data exist on the natural evolution. The rate of spontaneous remission appears to be less than in patients with less than 40% involvement. Vestey and Savin [ ] reviewed 50 patients
See Sponsor: Assiut University Information provided by (Responsible Party): Noura Ali, Assiut University Study Details Study Description Go to Brief Summary: Alopecia areata is the most frequent cause of inflammation-induced hairloss with prevalence from 0.1 to 0.2%. It has no age nor sex predilection . Clinically, alopecia areata presents as a well-circumscribed patch of sudden hairloss. It affects any hair bearing area. The most common affected site is the scalp. Based on site and extent, AA (...) months, using insulin syringes. Drug: Triamcinolone acetonide injection Intralesional Triamcinolone Acetonide injection Outcome Measures Go to Primary Outcome Measures : The incidence of patietns with hair regrowth [ Time Frame: 3 months ] measuring severity of alopecia tool score and dermoscopic examination Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members
Alopecia, androgenetic - male Alopecia, androgenetic - male - NICE CKS Share Alopecia, androgenetic - male: Summary Androgenetic alopecia describes a distinctive pattern of hairloss, which may occur in genetically predisposed men and is thought to be androgen dependent. In men, hairloss usually initially involves the front and sides of the scalp and progresses towards the back of the head. The underlying pathological process involves pigmented terminal hairs gradually being replaced (...) years of age, it affects about a third of white men. This increases to around 80% in men older than 70 years of age. Complications of androgenetic alopecia include adverse psychosocial effects. Hairloss progresses over time in untreated men. The rate of progression is unpredictable and some men eventually lose almost all of the scalp hairs, while others retain a considerable number particularly in the occipital and parietal areas above the ears. The diagnosis of androgenetic alopecia is usually
: Proportion of subjects achieving a SALT 50 or SALT 75 at Week 24 (n study ATI-501-AUAT-201) and maintaining that response at week 24 in ATI-502-AA-203 study. Mean Relative Percent Change from Baseline SALT score [ Time Frame: week 24 ] Mean Relative Percent Change from Baseline (from the current study ATI-502-AA-203) in Severity of Alopecia Tool (SALT). SALT score is on a percent scale where 0% is no hairloss and 100 % is total hairloss. A lower SALT score is a better outcome. A higher relative percent (...) in subjects with AA, AU or AT following 24 weeks of treatment with ATI-501 Oral Suspension or Placebo Suspension. To assess the ability of ATI-502 Topical Solution to maintain or improve hair regrowth in subjects previously treated with ATI-501 Oral Suspension or Placebo Suspension. Condition or disease Intervention/treatment Phase Alopecia Areata Alopecia Universalis Alopecia Totalis Drug: ATI 502 0.46% Topical Solution Phase 2 Detailed Description: This Phase 2, multicenter, open-label study
number of broken hairs. Primary hair shaft abnormalities are usually obvious on microscopic examination of the hair shaft. Scalp biopsy is indicated when alopecia persists and diagnosis is in doubt. Biopsy may differentiate scarring from nonscarring forms. Specimens should be taken from areas of active inflammation, ideally at the border of a bald patch. Fungal and bacterial cultures may be useful. Daily hair counts can be done by the patient to quantify hairloss when the pull test is negative (...) of the following diagnostic tests is often done to evaluate pigmented lesions? Shaving Deep excision Patch test Scraping NEWS & VIDEOS AAD: Isotretinoin Exposure for Acne Not Linked to Depression Risk FRIDAY, March 1, 2019 (HealthDay News) -- For patients with acne, exposure to isotretinoin is not associated with an increased risk for being diagnosed with depression, according to a study... SOCIAL MEDIA Add to Any Platform Loading Topic Resources Alopecia is defined as loss of hair from the body. Hairloss